TY - JOUR
T1 - Role of circulating free Alu DNA in endometrial cancer
AU - Tanaka, Hideo
AU - Tsuda, Hiroshi
AU - Nishimura, Sadako
AU - Nomura, Hiroyuki
AU - Kataoka, Fumio
AU - Chiyoda, Tatsuyuki
AU - Tanaka, Kyoko
AU - Iguchi, Yoko
AU - Susumu, Nobuyuki
AU - Aoki, Daisuke
PY - 2012/1
Y1 - 2012/1
N2 - Background: Endometrial cancer (EC) is the most common cancer of the female genital tract. However, no screening method for EC has been established yet. In this study, we evaluated the cell-free DNA in EC. Methods: Fifteen healthy individuals, 9 with benign gynecologic diseases, and 53 with ECs were included in this study. Alu sequences in free DNA fragments were used as surrogate markers, and cell-free DNA density was measured by quantitative real-time polymerase chain reaction. Results: The cell-free DNA levels in ECs tended to be higher than in benign condition (healthy individuals + benign gynecologic diseases, n = 24; P = 0.095). There was no significant difference in cell-free DNA among stage or histological grade of EC, and no significant change in cell-free DNA before and after operation (P = 0.25): Moreover, in 19 ECs, cell-free DNA decreased after operation, however, in 6 ECs, cell-free DNA did not decrease. Three ECs recurred, and cell-free DNA did not decrease in these cases. Conclusions: Measurement of cell-free DNA is not useful for EC screening; however, the change of cell-free DNA in a patient may be a prognostic biomarker of EC.
AB - Background: Endometrial cancer (EC) is the most common cancer of the female genital tract. However, no screening method for EC has been established yet. In this study, we evaluated the cell-free DNA in EC. Methods: Fifteen healthy individuals, 9 with benign gynecologic diseases, and 53 with ECs were included in this study. Alu sequences in free DNA fragments were used as surrogate markers, and cell-free DNA density was measured by quantitative real-time polymerase chain reaction. Results: The cell-free DNA levels in ECs tended to be higher than in benign condition (healthy individuals + benign gynecologic diseases, n = 24; P = 0.095). There was no significant difference in cell-free DNA among stage or histological grade of EC, and no significant change in cell-free DNA before and after operation (P = 0.25): Moreover, in 19 ECs, cell-free DNA decreased after operation, however, in 6 ECs, cell-free DNA did not decrease. Three ECs recurred, and cell-free DNA did not decrease in these cases. Conclusions: Measurement of cell-free DNA is not useful for EC screening; however, the change of cell-free DNA in a patient may be a prognostic biomarker of EC.
KW - Endometrial cancer
KW - Screening
KW - Serum biomarker
UR - https://www.scopus.com/pages/publications/84863294104
UR - https://www.scopus.com/inward/citedby.url?scp=84863294104&partnerID=8YFLogxK
U2 - 10.1097/IGC.0b013e3182328c94
DO - 10.1097/IGC.0b013e3182328c94
M3 - Article
C2 - 22146763
AN - SCOPUS:84863294104
SN - 1048-891X
VL - 22
SP - 82
EP - 86
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 1
ER -